Indiana University Foundation, Inc.

City of Hope Launches Clinical Trial Testing Osteoporosis Drug for Type 1 Diabetes Treatment

2 months ago

• City of Hope has initiated a phase 1/2 clinical trial investigating whether denosumab, an FDA-approved osteoporosis medication, can protect and regenerate insulin-producing beta cells in early-stage type 1 diabetes patients. • The multicenter, randomized trial will enroll 45 adults with early-stage type 1 diabetes across three research centers, with participants receiving either denosumab injections or placebo over 12 months to evaluate effects on beta cell function. • Researchers discovered that the RANKL/RANK pathway targeted by denosumab in bone treatment also affects beta cells, suggesting the drug could potentially slow disease progression and improve blood sugar control in diabetic patients.

Novel Immunotherapy Combinations Show Promise in Advanced Thymic Cancers

3 months ago

• Recent clinical trials demonstrate promising results for pembrolizumab plus lenvatinib combination in advanced B3-thymoma and thymic carcinoma, achieving an 88.4% progression-free survival rate at 5 months. • Researchers are actively investigating multiple immunotherapy combinations and antibody-drug conjugates, including sacituzumab govitecan, to advance treatment options for thymic epithelial tumors. • Experts emphasize the critical importance of multidisciplinary collaboration and precise diagnosis in managing thymic cancers, with ongoing research focused on understanding paraneoplastic autoimmune disorders.

Syrenity Mental Health App Shows Promise in Reducing Depression Symptoms in Indiana University Study

3 months ago

• A clinical trial of 135 participants at Indiana University demonstrated that Syrenity app users showed positive trends in reducing depression symptoms compared to non-users over a six-week period. • The science-based mental health app, developed by Syra Health, showed improvements in users' cognitive reappraisal abilities and healthier emotional expression patterns compared to the control group. • The study, led by Dr. Lorenzo-Luaces, notably included a diverse participant pool with 30% racial-ethnic minorities, addressing multiple mental health conditions simultaneously.

Adverse Events Linked to Better Survival Outcomes in Enfortumab Vedotin Treatment for Urothelial Cancer

3 months ago

• New research reveals patients experiencing neuropathy, skin rash, or hyperglycemia while taking Enfortumab Vedotin showed significantly improved progression-free survival in metastatic urothelial carcinoma treatment. • Study of 83 patients demonstrated extended progression-free survival of up to 15.9 months in those experiencing specific adverse events, compared to 4.5 months in those without these effects. • Findings were presented at the 2025 ASCO Genitourinary Cancers Symposium, following the FDA's recent approval of Enfortumab Vedotin with Pembrolizumab for advanced urothelial cancer.

INOVIO Advances DNA Medicine Pipeline with Focus on INO-3107 BLA Submission for RRP

4 months ago

• INOVIO plans to submit a Biologics License Application (BLA) to the FDA for INO-3107 by mid-2025, seeking priority review for recurrent respiratory papillomatosis. • Retrospective data showed that 50% of RRP patients treated with INO-3107 achieved complete response, requiring no surgery two to three years post-treatment. • INOVIO aims to initiate a confirmatory trial for INO-3107 at approximately 20 U.S. academic centers, enrolling around 100 patients. • The company is progressing with its commercial readiness plans, targeting a potential launch of INO-3107 by the end of 2025, pending regulatory approval.

ARPA-H Funds Multi-Institutional Consortium to Cure Blindness Through Eye Transplantation

6 months ago

• The University of Colorado Anschutz Medical Campus will receive up to $46 million from ARPA-H to advance vision-restoring human whole eye transplantation. • The project aims to achieve the first successful vision recovery in six human whole eye transplants by 2030, addressing optic nerve regeneration challenges. • The multi-disciplinary team includes experts from Johns Hopkins, University of Wisconsin, and the National Eye Institute, focusing on innovative technologies. • The Foundation Fighting Blindness will strategically align the consortium's progress with program requirements, driving advancements in treating blinding diseases.

Real-World Data Show Resmetirom Mirrors Clinical Trial Success in MASH Patients

6 months ago

• Real-world data from 72 MASH patients prescribed resmetirom show clinical characteristics and noninvasive test results consistent with phase 3 trial data. • The study, conducted across two US tertiary care centers, suggests resmetirom's effectiveness in clinical practice mirrors its performance in controlled trials. • Findings indicate appropriate patient selection for resmetirom can be achieved using noninvasive testing, potentially negating the need for liver biopsies. • The data offers a promising glimpse into resmetirom's utility in routine clinical settings, with ongoing data collection aimed at further validating its real-world efficacy.

Landmark Discovery: Cisplatin-Based Therapy Transforms Testicular Cancer Treatment Over 50 Years

8 months ago

• In 1974, Dr. Lawrence Einhorn at Indiana University pioneered a cisplatin-based chemotherapy regimen, revolutionizing testicular cancer treatment. • The innovative approach dramatically increased survival rates from 5% to over 95%, marking a paradigm shift in oncology and cancer research. • Einhorn's work spurred increased investment in oncology, influencing the development of new treatments like immunotherapy for solid tumors. • Continuous refinements to the regimen have minimized side effects and shortened therapy duration, enhancing patient outcomes and quality of life.

Blood Biomarkers Show Promise in Predicting Suicidality and Guiding Personalized Treatment

9 months ago

• Researchers have identified blood biomarkers that can predict suicidal ideation and future hospitalization for suicidality, offering a new tool for risk assessment. • The study used a multi-cohort approach, including discovery, validation, and testing phases, to ensure the robustness of the identified biomarkers. • Pathway analysis revealed that these biomarkers are involved in key biological processes related to psychiatric disorders, providing insights into the underlying mechanisms of suicidality. • The findings support the development of personalized treatment strategies based on an individual's biomarker profile, potentially improving outcomes for those at risk.

One-Week Elderberry Juice Treatment Increases Postprandial Carbohydrate Oxidation

2 years ago

A pilot study found that consuming 100% elderberry juice for one week significantly increased postprandial carbohydrate oxidation in overweight and obese adults, without affecting serum glucose or insulin levels. The study suggests elderberry juice could influence metabolic flexibility, though further research is needed to confirm these findings.